SGNA 2024

Harris College of Nursing and Heath Services Texas Christian University

Introduction

Clostridioides difficile infection (CDI) is a global healthcare concern, causing between 15,000–30,000 deaths and healthcare costs exceeding \$4.8 billion annually [1]. Even with appropriate treatment of CDI with standard-of-care (SoC) antibiotic therapy, first recurrences continue in up to 35% of patients following an initial episode [2-5]. While treating the CDI, SoC antibiotics disrupt the gut microbiota, increasing the risk for further recurrent CDI (rCDI). Microbial restoration with live biotherapeutic products may restore the diversity and composition of the gut microbiota to decrease the likelihood of rCDI.

Fecal Microbiota, live-jslm (RBL) is a rectally administered, pre-packaged, live biotherapeutic approved in November 2022 for the prevention of recurrence of Clostridioides difficile infection (rCDI) in adults [6]. Clinical trial data indicates success in prevention of recurrence [7,8] for RBL, the first FDA-approved microbiota product. Study is warranted of whether RBL, a novel therapy in preventing rCDI, may pose challenges in routine clinical administration, particularly with Gastroenterology (GI) and Infectious Disease (ID) practices or other specialties not commonly providing rectally administered therapies.

Objectives

The objective of this study is to develop and report implementation of a simple administration protocol of RBL for rCDI prevention in routine clinical practice

Methods

Study Design: Retrospective, multicenter cohort study conducted in physician office infusion centers (POICs) in the United States.

Patient Population: All patients who received at least one dose of RBL from February 2023 through August 2023.

Protocol: A multi-disciplinary protocol was developed for provision of RBL through POICs. Development included the following:

- Protocol designed by Nursing, Pharmacy, Business Office (BO), Operations, and Purchasing
- Certificate of Medical Necessity (CMN) for insurance approval
- Order set
- Guidelines for use:
 - Referral and order management
 - Notification to BO and Clinical Team of a new urgent (STAT) order
 - Insurance approval and submission of co-pay assistance, if applicable
 - Scheduling of patient with coordination of antibiotic discontinuation
 - Acquisition of RBL
 - Pre-appointment confirmation
 - Appointment procedures with preparation and administration

Data collection: Electronic medical records (EMR), administration records and internal databases were queried, and the following data collected:

- Patient demographics, including payor detail
- History of present illness (HPI) for current and past episodes of CDI
- CDI stool test results and antimicrobial therapy
- Time from order to treatment
- Nursing assessment for RBL administration
- Adverse effects during the procedure

Data Analysis: Continuous and categorical variables were reported using mean ±standard deviation (SD) or median with interquartile range (IQR) and frequency (percentage), respectively.

Real World Experience of Simple Administration of a Novel Fecal Microbiome **Replacement for Prevention of Recurrent Clostridioides difficile**

Kathy A. Baker Ph.D., APRN¹; Timothy E. Ritter, MD²; Jonathan A. Rosenberg, MD³; Richard L. Hengel MD⁴; Sujatha Krishan, MD⁵ Lucinda J. Van Anglen, BS, PharmD⁶; Kelly E. Hanna, PharmD⁶; Amy Guo, PhD⁷; Mielad Moosapanah, PharmD⁷; Kevin W. Garey, PharmD⁸

Table 1. Patient Characteristics

Characteristic

Age, years (mean±SD) Age ≥65 years Female CDI episodes, including current, me SoC Antibiotic for the current episod Vancomycin Fidaxomicin Fidaxomicin and vancomycin Other* lealth Insurance Commercial Medicare, Traditional Medicare Advantage Plan

vancomycin + metronidazole (n=1), unknown antibiotic

Figure 1. Certificate of Medical Necessity




Table 2. Treatment Criteria

RBL Protocol Treatment Criteria

Primary Diagnosis: Enterocolitis due to Clostridium difficile, recurrent (ICD-10 Code: A04.71) Patient Age (required to be ≥18 years) **Completion of Certificate of Medical Necessity, including the following:** History and Physical

Clear indication of current episode of recurrent CDI No. of prior CDI episodes and dates Positive stool test(s) for current episode, with type of test and dates Antibiotic therapy for the current CDI episode Antibiotic regimen and planned stop date (to plan for RBL administration)

Society of Gastroenterology Nurses and Associates (SGNA) Annual Course 2024

¹Harris College of Nursing and Health Sciences, Texas Christian University; ²GI Alliance, Southlake, TX; ³GI Alliance, Highland Park, IL; ⁴Atlanta ID Group, Atlanta, GA; ⁵DFW Infectious Disease, Dallas, TX; ⁶Healix Infusion Therapy, Sugar Land, TX; ⁷Ferring Pharmaceuticals; ⁸University of Houston College of Pharmacy, Houston, TX

Study Cohort

• 25 patients from 12 POICs in 8 states received RBL through 8/31/2023. • Patients received treatment in GI POICs (n=14) and in ID POICs (n=11).

	Results (N=25)	
	69±17	
	17 (68%)	
	17 (68%)	
dian (IQR)	4 (3-4)	
de of CDI		
	12 (48%)	
	8 (32%)	
	4 (16%)	
	2 (8%)	
	9 (36%)	
	9 (36%)	
	7 (28%)	
(n=1); Data are presented as no. (%) unless otherwise indicated.	-

- Confirmation of control of symptoms with the current episode

Logistical Flow

Figure 2. Process Flow




Table 2 Clinical and Administration Drate and

RE	3L Clinical Protocol
Ap	opointment Coordination
	Ensure the SoC antibiotic has been discontinued at least 24-72 hours prior to RBL administrat
	Order RBL 2-4 days prior to the appointment for overnight delivery Tuesday through Friday.
	Store RBL in the refrigerator immediately upon receipt. (Outside of a -70°C environment, RBL stable for 5 days refrigerated.)
Pr	e-appointment Confirmation (24 hours prior)
	Confirm patient does not have active diarrhea or continuing CDI symptoms.
	Confirm the SoC antibiotic has been or will be discontinued at least 24-72 hours before the appointment.
	Thaw RBL in the refrigerator for 24 hours prior to the appointment.
	Request patient to empty bladder or bowel prior the appointment, but not to perform any bowel prep.
RE	3L Administration
	Greet patient and room them in a private room with an exam table.
	Have patient empty bladder and bowels if not done prior to appointment.
	Don proper PPE and follow infection control guidelines for Clostridioides difficile.
	Retrieve RBL from the refrigerator just prior to administration.
	Place underpad on the exam table and position patient in a position as noted in Figure 3.
	Prepare RBL for administration with attachment of provided tubing and apply lubricant to tip.
	Administer single dose of RBL 150 mL immediately via gravity flow over 5 minutes.
	Keep patient in the same position and observe for 15 minutes to minimize cramping.
	Discharge patient from the clinic (may use bathroom prior to leaving if needed).

Administration


Knee-chest position: Kneel, then

lower head and chest forward until

left side of face is resting on surface

with left arm folded comfortably.

Figure 3. Administration Diagrams



Left-side position: Lie on left side with knee bent and arms resting comfortably.

Figure 4. RBL Order




Table 4. Administration Outcomes

	Cohort	
Parameter	No. of pts (N=25)*	Result
Time from order to RBL administration, median days (IQR)	25	19 (17-30)
Instillation time via gravity flow, minutes, median (IQR)	12	6 (5-12)
Observation time, minutes	17	15
Administration position	16	-
Left lateral	-	15
Right lateral	-	1
Knee-Chest	-	0
Healthcare provider administering	22	-
Registered Nurse	-	16
Licensed Vocational Nurse	-	3
Nurse Practitioner	-	2
Physician	-	1
Adverse effects reported during the procedure	22	0
Reports of rectal leakage	22	0
Patients with bowel movement after the procedure	22	4

This multicenter study involved the development of a simple protocol for administration of RBL, with subsequent analysis of the protocol. RBL is a rectally administered, pre-packaged, live biotherapeutic for the prevention of rCDI in adults.

- Protocol key success factors were:

 - administration
- administration of RBL.
- occurred.

- and safe.
- prevention of rCDI.



Discussion

• 25 patients received RBL following development and initiation of a protocol for use in 12 physician office infusion centers.

• Patients were older (69±17 years), majority female (68%) and most (64%) Medicare (Traditional or Medicare Advantage) recipients. Patients had a median of 4 episodes of CDI, including the current episode. Vancomycin was the most used SoC antibiotic for treatment of CDL

• Rapid compilation of required records for insurance approval following identification of rCDI. Median approval was 19 days from order to treatment

• Training for the nurses of the protocol and procedures for management, drug ordering, patient communication, and

Prompt order placement and receipt of RBL to meet appointments.

• The nurses confirmed completion of SoC at least 24-72 hours prior to

• Administration of RBL was performed most often by registered nurses.

• RBL was instilled mostly in the left lateral position and completed in 6 minutes with 15 minutes of observation. No leakage or adverse events

• All patients adhered to appointments and received RBL as planned.

Conclusion

• Development of a standardized protocol was critical in facilitation of RBL therapy in physician office infusion centers, particularly for nurses not familiar with rectal administration.

• Overall patient visit time and administration of RBL was brief

• RBL holds promise as a simple office-based therapy for the

References

McDonald LC, et al. Clin Infect Dis. 2018; 66:e1-e48.

2. Johnson S, et al. Clin Infect Dis. 2021;73(5):e1029-44.

3. Guh A, et al. N Engl J Med. 2020; 382:1320-1330

4. Cornely OA, et al. Clin Infect Dis. 2012; 55:S154-61.

5. Ma GK, et al. Ann Intern Med. 2017; 167:152-8.

6. Rebyota (fecal microbiota, live - jslm) [package insert]. Roseville, MN:

Ferring Pharmaceuticals; 2022.

Dubberke ER, et al. Infect Dis Ther. 2023; 12:703–710.

8. Khanna S, et al. Drugs. 2022; 82:1527–1538.